Optinose CEO sells over $36k in company stock By Investing.com


© Reuters.

OptiNose, Inc. (NASDAQ:OPTN) Chief Executive Officer Ramy A. Mahmoud has recently engaged in transactions involving the company’s stock, according to the latest SEC filings. Mahmoud sold 19,198 shares of common stock at a price of $1.88 per share, resulting in a total sale value of $36,092.

The transactions took place on March 18, following the vesting of restricted stock units (RSUs) as part of the company’s equity incentive plan. The sale was conducted to cover tax withholding obligations related to the vesting of these RSUs. It’s important to note that this sale was a mandatory action as per the issuer’s award agreement, and was not a discretionary trade by Mahmoud.

In addition to the sales, Mahmoud also acquired 6,114 shares of OptiNose stock at no cost. These shares represent the vesting of performance-based restricted stock units granted on March 6, 2020. The vesting was contingent upon the achievement of certain milestones connected to the company’s development programs. Half of these performance RSUs vested previously in June 2022, and the remaining balance vests in eight equal quarterly installments, provided Mahmoud continues his service with OptiNose.

Following these transactions, Mahmoud’s direct ownership of OptiNose shares stands at 1,331,278. Additionally, he has an indirect ownership interest in 172,422 shares through The Ramy Mahmoud 2014 Trust for Cynthia Mahmoud.

OptiNose, Inc., headquartered in Yardley, Pennsylvania, is a specialty pharmaceutical company engaged in the development and commercialization of products for patients treated by ear, nose, throat (ENT), and allergy specialists. The company’s stock trading symbol is OPTN.

InvestingPro Insights

As investors assess the recent stock transactions of OptiNose, Inc. (NASDAQ:OPTN) CEO Ramy A. Mahmoud, it’s crucial to consider the company’s financial health and market performance. InvestingPro data reveals a mixed picture with some notable highlights. OptiNose boasts an impressive gross profit margin of 87.84% for the last twelve months as of Q4 2023, emphasizing their ability to maintain profitability at the core operational level. Despite this strength, the company has not been profitable over the same period, with a negative P/E Ratio of -5.94 indicating earnings challenges.

On the market front, OptiNose’s stock price has shown resilience, with a strong return over the last month of 41.76% and over the last three months of 68.26%. This performance is particularly interesting given one of the InvestingPro Tips that highlights the stock’s tendency to move in the opposite direction of the market. This could suggest a unique investor sentiment or company-specific factors driving the stock’s behavior.

For investors looking to delve deeper into OptiNose’s financials and stock performance, more InvestingPro Tips are available, including insights on the company’s short-term obligations versus liquid assets and analyst expectations for profitability. With a current market cap of 206.15M USD, OptiNose’s stock could be an intriguing option for those willing to explore its potential further. To access additional InvestingPro Tips, investors can visit InvestingPro and take advantage of the PRONEWS24 coupon code for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


Source link

Check Also

Investing in CSC Steel Holdings Berhad (KLSE:CSCSTEL) five years ago would have delivered you a 70% gain

It might be of some concern to shareholders to see the CSC Steel Holdings Berhad …

Leave a Reply

Your email address will not be published. Required fields are marked *